Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Sino Universal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin and Sino Universal Sign Deal for Tiotropium DPI Supply in China
Details : Under the licensing agreement, SUP will holds the right for the commercialization of Spiriva HandiHaler-Generic (Tiotropium Bromide) in the Chinese market for the treatment of COPD.
Product Name : Spiriva HandiHaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 16, 2025
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Sino Universal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD
Details : Tiotropium bromide inhalation powder exhibits pharmacological effects through inhibition of M3-receptors and used for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Spiriva Handihaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Tiotropium Dry Powder for Inhaler for the Treatment of COPD in the United States
Details : Tiotropium bromide Inhalation powder for capsule, a generic equivalent of Spiriva HandiHaler, inhibits M3-receptors, that is indicated for the treatment of chronic obstructive pulmonary disease.
Product Name : Spiriva Handihaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval from U.S. FDA for Tiotropium Dry Powder Inhaler
Details : Spiriva Handihaler (tiotropium bromide), an inhalation powder, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease and asthma.
Product Name : Spiriva Handihaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to bolster access to healthcare by expanding the availability of Tiotropium Bromide Inhalation Powder, to COPD patients in the US.
Product Name : Spiriva Handihaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Announces Health Canada Approval of Tiotropium Bromide Inhalation Powder for Treatment of COPD
Details : Spiriva-Generic (tiotropium bromide) inhalation powder is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Product Name : Spiriva Handihaler-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2023
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide,Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is a prescription medicine used long term, 2 puffs 1 time each day, in controlling symptoms in adults with chronic obstructive pulmonary disease (COPD).
Product Name : Stiolto Respimat
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Tiotropium Bromide,Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tavulus® is a long-acting bronchodilator that helps to open the airways and makes it easier for air to get in and out of the lungs. It also works to prevent sudden, short-term worsening of COPD symptoms.
Product Name : Tavulus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Agreement
LANNETT Expands Respiratory Pipeline, Signs Exclusive Commercialization
Details : Lannett Company has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 29, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name. Tiogiva® in UK Tiogiva® is the bioequivalent version of Boehringer Ingelheim’s Spiriva® Handihaler®. Tiotropium Bromide DPI is used in the treatment of COPD.
Product Name : Tiogiva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable